Gene · 634
Papers3,222
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
481 to 500 of 3,222
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development. | Clin Transl Oncol | 2023 | 36781600 | PubTator, text mining | PubMed |
| Integrative proteomic characterization of adenocarcinoma of esophagogastric junction. | Nat Commun | 2023 | 36774361 | PubTator, text mining | PubMed |
| Immune landscape and immunotherapy of hepatocellular carcinoma: focus on innate and adaptive immune cells. | Clin Exp Med | 2023 | 36773210 | PubTator, text mining | PubMed |
| Influence of Butyrate on Impaired Gene Expression in Colon from Patients with High Blood Pressure. | Int J Mol Sci | 2023 | 36768972 | PubTator, text mining | PubMed |
| Natural Killer Cell-Based Immunotherapy against Glioblastoma. | Int J Mol Sci | 2023 | 36768432 | PubTator, text mining | PubMed |
| Key Genes of Immunity Associated with Pterygium and Primary Sjögren's Syndrome. | Int J Mol Sci | 2023 | 36768371 | PubTator, text mining | PubMed |
| The Variations' in Genes Encoding TIM-3 and Its Ligand, Galectin-9, Influence on ccRCC Risk and Prognosis. | Int J Mol Sci | 2023 | 36768365 | PubTator, text mining | PubMed |
| MicroRNAs with Multiple Targets of Immune Checkpoints, as a Potential Sensitizer for Immune Checkpoint Inhibitors in Breast Cancer Treatment. | Cancers (Basel) | 2023 | 36765782 | PubTator, text mining | PubMed |
| Na, K-ATPase α1 cooperates with its endogenous ligand to reprogram immune microenvironment of lung carcinoma and promotes immune escape. | Sci Adv | 2023 | 36763655 | PubTator, text mining | PubMed |
| Isolation and proteomic profiling of urinary exosomes from patients with colorectal cancer. | Proteome Sci | 2023 | 36759883 | PubTator, text mining | PubMed |
| A mechanistic evaluation of human beta defensin 2 mediated protection of human skin barrier in vitro. | Sci Rep | 2023 | 36755116 | PubTator, text mining | PubMed |
| Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer. | Clin Cancer Res | 2023 | 36749873 | PubTator, text mining | PubMed |
| CEACAMS 1, 5, and 6 in disease and cancer: interactions with pathogens. | Genes Cancer | 2023 | 36741860 | PubTator, text mining | PubMed |
| Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases. | J Immunol Res | 2023 | 36741231 | PubTator, text mining | PubMed |
| Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma. | J Transl Med | 2023 | 36732815 | PubTator, text mining | PubMed |
| Correction to: Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells. | Cancer Gene Ther | 2023 | 36732550 | PubTator, text mining | PubMed |
| Relationships of tumor differentiation and immune infiltration in gastric cancers revealed by single-cell RNA-seq analyses. | Cell Mol Life Sci | 2023 | 36729271 | PubTator, text mining | PubMed |
| Secreted proteins MDK, WFDC2, and CXCL14 as candidate biomarkers for early diagnosis of lung adenocarcinoma. | BMC Cancer | 2023 | 36721112 | PubTator, text mining | PubMed |
| Neutrophil CEACAM1 determines susceptibility to NETosis by regulating the S1PR2/S1PR3 axis in liver transplantation. | J Clin Invest | 2023 | 36719377 | PubTator, text mining | PubMed |
| Avoid being trapped by your liver: ischemia-reperfusion injury in liver transplant triggers S1P-mediated NETosis. | J Clin Invest | 2023 | 36719374 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/634/papers?page=25